{
    "clinical_study": {
        "@rank": "168306", 
        "arm_group": [
            {
                "arm_group_label": "Part 1 - Severe renal impairment", 
                "arm_group_type": "Experimental", 
                "description": "Part 1 - Group 1: subjects with severe renal impairment or end-stage renal disease (ESRD), not on dialysis: Estimated glomerular filtration rate (eGFR) between 15-29 mL/min/1.73 m2 or <15 mL/min/1.73m\u00b2 will be administered GLPG0634 100 mg once daily for 10 days"
            }, 
            {
                "arm_group_label": "Part 1: Normal renal function", 
                "arm_group_type": "Experimental", 
                "description": "Part 1 - Group 2: subjects with normal renal function: eGFR \u226590 mL/min/1.73m\u00b2 will be administered GLPG0634 100 mg once daily for 10 days"
            }, 
            {
                "arm_group_label": "Part 2 - Mild renal impairment", 
                "arm_group_type": "Experimental", 
                "description": "Part 2 - Group 3: subjects with mild renal impairment: eGFR between 60-89 mL/min/1.73 m\u00b2 will be administered GLPG0634 100 mg once daily for 10 days"
            }, 
            {
                "arm_group_label": "Part 2 - Moderate renal impairment", 
                "arm_group_type": "Experimental", 
                "description": "Part 2 - Group 4:subjects with moderate renal impairment: eGFR between 30-59 mL/min/1.73 m\u00b2 will be administered GLPG0634 100 mg once daily for 10 days"
            }, 
            {
                "arm_group_label": "Part 2 - Normal renal function", 
                "arm_group_type": "Experimental", 
                "description": "Part 2 - Group 5: subjects with normal renal function: eGFR \u226590 mL/min/1.73 m\u00b2 will be administered GLPG0634 100 mg once daily for 10 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This will be an open label study to assess the influence of renal impairment on the\n      pharmacokinetics (PK) of GLPG0634 and its metabolite after once daily oral administrations\n      of 100 mg GLPG0634 for 10 days in subjects with renal impairment and matched healthy\n      controls.\n\n      Also, safety and tolerability of once daily oral doses of GLPG0634 for 10 days in subjects\n      with renal impairment and matched healthy controls will be evaluated."
        }, 
        "brief_title": "Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Impairment", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "detailed_description": {
            "textblock": "The study will be divided in two parts.\n\n      In Part 1, 3 subjects with severe renal impairment or end-stage renal disease (ESRD) not yet\n      requiring dialysis (Group 1) will be recruited first. Thereafter, 3 subjects with normal\n      renal function (Group 2) will be recruited. If a substantial effect on the PK in renal\n      impaired subjects is observed on Day 10, the sponsor may elect to stop Part 1 of the study\n      without enrolling the complete set of subjects and Part 2 will be initiated. In case no\n      substantial effect on the PK is observed, 3 further subjects in both Group 1 and 2 will be\n      recruited and analysed. If a substantial effect on the PK is observed, the study will\n      proceed to Part 2. Part 2 of the study will not be conducted, if in Part 1 no substantial\n      difference in PK is seen.\n\n      In Part 2, Group 3 (mild renal impairment) and Group 4 (moderate renal impairment) will be\n      recruited first. After completion of the mild and moderate impairment groups, Group 5\n      (normal renal function) will be recruited."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female white subjects between 18-79 years of age (inclusive)\n\n          -  Subjects must have a BMI between 18-34 kg/m\u00b2, inclusive\n\n          -  Part 1, Group 1: subject with severe renal impairment or ESRD, not on dialysis : eGFR\n             between 15-29 mL/min/1.73 m2 or <15 mL/min/1.73m\u00b2\n\n          -  Part 1, Group 2: subject with normal renal function: eGFR \u226590 mL/min/1.73m\u00b2\n\n          -  Part 2, Group 3: subject with mild renal impairment: eGFR between 60-89 mL/min/1.73\n             m\u00b2\n\n          -  Part 2, Group 4:subject with moderate renal impairment: eGFR between 30-59\n             mL/min/1.73 m\u00b2\n\n          -  Part 2, Group 5: subject with normal renal function: eGFR \u226590 mL/min/1.73 m\u00b2\n\n          -  Subjects must be judged to be in good health (subjects with normal renal function)/in\n             a stable condition and acceptable for study participation (subjects with renal\n             impairment) based upon the results of a medical history, physical examination, vital\n             signs, 12-lead ECG, and laboratory profile\n\n        Exclusion Criteria:\n\n          -  A subject with a known hypersensitivity to ingredients of the study medication or a\n             significant allergic reaction to any drug\n\n          -  Subject has previously participated in a GLPG0634 study or has previously received\n             GLPG0634\n\n          -  Concurrent participation or participation within 8 weeks prior to the initial study\n             drug administration in a drug/device or biologic investigational research study\n\n          -  A subject with active drug or alcohol abuse within 2 years prior to the initial study\n             drug administration\n\n          -  A subject who has a current child wish\n\n          -  Female subject less than 6 months post-partum, post-abortion or post-lactation prior\n             to study drug administration or is pregnant or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084199", 
            "org_study_id": "GLPG0634-CL-106", 
            "secondary_id": "2013-004407-40"
        }, 
        "intervention": {
            "arm_group_label": [
                "Part 1 - Severe renal impairment", 
                "Part 1: Normal renal function", 
                "Part 2 - Mild renal impairment", 
                "Part 2 - Moderate renal impairment", 
                "Part 2 - Normal renal function"
            ], 
            "description": "100 mg oral tablet, intake once daily for 10 days", 
            "intervention_name": "GLPG0634", 
            "intervention_type": "Drug", 
            "other_name": "GLPG0634 tablets"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "contact": {
                "email": "rd@glpg.com"
            }, 
            "facility": {
                "address": {
                    "city": "Kiel", 
                    "country": "Germany"
                }, 
                "name": "CRS Clinical Research Services Kiel GmbH"
            }, 
            "investigator": {
                "last_name": "Atef Halabi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "5", 
        "official_title": "Study to Evaluate the Pharmacokinetics, Safety, Tolerability of 100 mg Multiple Doses of GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects", 
        "overall_contact": {
            "email": "rd@glpg.com", 
            "last_name": "Galapagos Clinical Trial Information Desk"
        }, 
        "overall_official": {
            "affiliation": "Galapagos NV", 
            "last_name": "Pille Harrison, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Cmax of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function", 
                "measure": "Maximum observed plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)"
            }, 
            {
                "description": "AUC0-24h of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function", 
                "measure": "Area under the plasma drug concentration-time curve over 24 hours (AUC0-24h)", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084199"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Ae of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function", 
                "measure": "Cumulative amount excreted in urine expressed in \u03bcg and % of the dose administered (Ae)", 
                "safety_issue": "No", 
                "time_frame": "Between dosing on Day 1 up to 48 h after dosing on Day 10 (Day 12)"
            }, 
            {
                "description": "CLR (calculated as Ae/AUC, where Ae and AUC are calculated over the same interval) of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function", 
                "measure": "Renal clearance (CLR)", 
                "safety_issue": "No", 
                "time_frame": "Between dosing on Day 1 up to 48 h after dosing on Day 10 (Day 12)"
            }, 
            {
                "description": "C24h of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function", 
                "measure": "Plasma concentration observed at 24 h post-dose (C24h)", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)"
            }, 
            {
                "description": "Cavg (calculated as AUC0-24h/24h) of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function", 
                "measure": "Average plasma concentration (Cavg)", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)"
            }, 
            {
                "description": "Tmax of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function", 
                "measure": "Time of occurrence of Cmax (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)"
            }, 
            {
                "description": "AUC0-z of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function", 
                "measure": "Area under the plasma drug concentration-time curve from zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-z)", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)"
            }, 
            {
                "description": "AUC0-\u221e of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function", 
                "measure": "Area under the plasma drug concentration-time curve, extrapolated to infinity (AUC0-\u221e)", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)"
            }, 
            {
                "description": "t1/2,\u03bbz (calculated from (ln 2)/\u03bbz being the apparent terminal rate constant) of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function", 
                "measure": "Apparent terminal half-life (t1/2,\u03bbz)", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)"
            }, 
            {
                "description": "R (metabolite over parent ratio of AUC0-24h) after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function", 
                "measure": "Metabolite over parent ratio of AUC0-24h (R)", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)"
            }, 
            {
                "description": "Rac (calculated as AUC0-24h Day 10/AUC0-24h Day 1) after dosing in subjects with renal impairment versus subjects with normal renal function", 
                "measure": "Accumulation ratio (Rac)", 
                "safety_issue": "No", 
                "time_frame": "Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of adverse events (AEs)", 
                "measure": "The number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 10 days after last dose (Day 20)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal laboratory parameters", 
                "measure": "The number of subjects with abnormal laboratory parameters", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 10 days after last dose (Day 20)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal vital signs", 
                "measure": "The number of subjects with abnormal vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 10 days after last dose (Day 20)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal electrocardiogram (ECG)", 
                "measure": "The number of subjects with abnormal electrocardiogram (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 10 days after last dose (Day 20)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal physical examination", 
                "measure": "The number of subjects with abnormal physical examination", 
                "safety_issue": "Yes", 
                "time_frame": "From screening up to 10 days after last dose (Day 20)"
            }
        ], 
        "source": "Galapagos NV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galapagos NV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}